|Mr. Lars Fruergaard Jørgensen||Pres & CEO||N/A||N/A||1966|
|Mr. Karsten Munk Knudsen||Exec. VP & CFO||N/A||N/A||1971|
|Dr. Mads Krogsgaard Thomsen||Exec. VP & Chief Science Officer||N/A||N/A||1960|
|Mr. Henrik Ehlers Wulff||Exec. VP and Head of Product Supply, Quality & IT||N/A||N/A||1970|
|Ms. Camilla Sylvest||Exec. VP and Head of Commercial Strategy & Corp. Affairs||N/A||N/A||1972|
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases; and Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for liver-related cardio-metabolic diseases. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S’s ISS governance QualityScore as of 4 October 2019 is 5. The pillar scores are Audit: 1; Board: 3; Shareholder rights: 10; Compensation: 3.